Posterior Uveitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Posterior Uveitis - Pipeline Review, H2 2016

Posterior Uveitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Posterior Uveitis - Pipeline Review, H2 2016
Published Oct 30, 2016
65 pages — Published Oct 30, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Posterior Uveitis Pipeline Review, H2 2016, provides an overview of the Posterior Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. One of the types of uveitis is posterior uveitis. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Posterior Uveitis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Posterior Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Posterior Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 3 respectively.Posterior Uveitis.

Posterior Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Posterior Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Posterior Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Posterior Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Posterior Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Posterior Uveitis (Ophthalmology)

  
Source:
Document ID
GMDHC8626IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Posterior Uveitis Overview61
Therapeutics Development71
  Pipeline Products for Posterior Uveitis Overview71
Posterior Uveitis Therapeutics under Development by Companies81
Posterior Uveitis Pipeline Products Glance93
  Late Stage Products91
  Clinical Stage Products101
  Early Stage Products111
Posterior Uveitis Products under Development by Companies121
Posterior Uveitis Companies Involved in Therapeutics Development137
  Aciont Inc.131
  Neuroptis Biotech141
  Oculis ehf151
  pSivida Corp.161
  Regeneron Pharmaceuticals Inc171
  Sandoz International GmbH181
  Santen Pharmaceutical Co., Ltd.191
Posterior Uveitis Therapeutics Assessment209
  Assessment by Monotherapy Products201
  Assessment by Target212
  Assessment by Mechanism of Action232
  Assessment by Route of Administration252
  Assessment by Molecule Type272
Drug Profiles2923
  adalimumab biosimilar Drug Profile291
  dexamethasone acetate Drug Profile301
  dexamethasone sodium phosphate Drug Profile312
  EYS-606 Drug Profile331
  fluocinolone acetonide SR Drug Profile349
  NOP-3 Drug Profile431
  sarilumab Drug Profile445
  sirolimus Drug Profile493
Posterior Uveitis Dormant Projects521
Posterior Uveitis Discontinued Products531
Posterior Uveitis Product Development Milestones5410
  Featured News &Press Releases541
    Oct 04, 2016: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target541
    Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting541
    Aug 09, 2016: Primary Endpoint Met in pSivida's Utilization Study of New Medidur Inserter with Smaller Diameter Needle551
    Jul 27, 2016: pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)551
    Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve561
    May 02, 2016: pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe571
    Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis581
    Dec 28, 2015: pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial581
    Dec 22, 2015: pSivida Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis592
    Sep 28, 2015: pSivida Announces NDA for Medidur Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs611
    May 19, 2015: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis611
    Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis621
    Apr 15, 2013: Aciont To Present at ARVO 2013 Annual Meeting631
Appendix642
  Methodology641
  Coverage641
  Secondary Research641
  Primary Research641
  Expert Panel Validation641
  Contact Us641
  Disclaimer651

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Posterior Uveitis - Pipeline Review, H2 2016" Oct 30, 2016. Alacra Store. May 04, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Posterior-Uveitis-Pipeline-Review-H2-2016-2088-16755>
  
APA:
Global Markets Direct - Market Research. (2016). Posterior Uveitis - Pipeline Review, H2 2016 Oct 30, 2016. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Posterior-Uveitis-Pipeline-Review-H2-2016-2088-16755>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.